ITRM
Iterum Therapeutics plc
NASDAQ · Healthcare · Biotechnology · IE
$0.03
−10.98%Income statement
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 390.0K | — | — | — | — |
| Cost of Revenue | 1.1M | 254.0K | 1.8M | 1.8M | 2.1M |
| Gross Profit | (668.0K) | (254.0K) | (1.8M) | (1.8M) | (2.1M) |
| Operating Expenses | |||||
| R&D Expense | 3.8M | 10.5M | 38.2M | 15.8M | 8.6M |
| SG&A Expense | 15.6M | 8.0M | 7.5M | 12.8M | 13.8M |
| General & Admin Expense | 9.1M | 8.0M | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 254.0K | — | — | — | — |
| Total Operating Expenses | 19.6M | 18.4M | 45.7M | 28.6M | 22.4M |
| Cost and Expenses | 20.7M | 18.7M | 47.5M | 30.4M | 24.5M |
| Operating Income (EBIT) | (20.3M) | (18.7M) | (47.5M) | (30.4M) | (24.5M) |
| Non-Operating | |||||
| Interest Income | 133.0K | — | 1.4M | 2.4K | 4.5K |
| Interest Expense | 2.3M | — | — | 2.4M | 5.6M |
| Net Interest Income | (2.2M) | — | 1.4M | (2.4M) | (5.5M) |
| Other Non-Op Income/Expense | (6.4M) | (5.8M) | 9.7M | (13.8M) | (66.3M) |
| Non-Operating Income (excl Interest) | 4.1M | 3.3M | (11.1M) | 11.4M | 60.8M |
| EBT (Pre-Tax Income) | (26.7M) | (24.5M) | (37.8M) | (44.1M) | (90.9M) |
| Income Tax Expense | 276.0K | 240.0K | 613.0K | 301.0K | 705.0K |
| Bottom Line | |||||
| Net Income | (27.0M) | (24.8M) | (38.4M) | (44.4M) | (91.6M) |
| Earnings from Cont. Ops | (27.0M) | (24.8M) | (38.4M) | (44.4M) | (91.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (27.0M) | (24.8M) | (38.4M) | (44.4M) | (91.6M) |
| Per Share | |||||
| Basic EPS | ($0.75) | ($1.26) | ($2.96) | ($3.63) | ($8.41) |
| Diluted EPS | ($0.75) | ($1.26) | ($2.96) | ($3.63) | ($8.41) |
| Revenue Per Share | $0.01 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 45.8M | 19.7M | 13.0M | 12.2M | 10.9M |
| Diluted Shares Outstanding | 45.8M | 19.7M | 13.0M | 12.2M | 10.9M |
| Profitability Metrics | |||||
| EBITDA | (23.1M) | (21.7M) | (34.6M) | (40.0M) | (83.2M) |
| D&A | 1.3M | 284.0K | 1.8M | 1.8M | 2.1M |
| EBIT | (24.4M) | (22.0M) | (36.3M) | (41.8M) | (85.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2025